Final - June 23, 2021

PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

11:30 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

Overview of myocarditis and pericarditis

Update on COVID-19 vaccine safety, including myocarditis after mRNA vaccines 

VaST assessment

Dr. Matthew Daley (ACIP, WG Chair)

Dr. Matthew Oster (CDC/NCBDDD)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Grace Lee (ACIP, VaST Co-chair)

12:45

1:00 Dr. Megan Wallace (CDC/NCIRD)

2:15

2:30

3:00 Dr. Sara Oliver (CDC/NCIRD)

4:00

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:30 Dengue Vaccine 

Introduction

Acceptability of dengue vaccine in Puerto Rico

Implementation of dengue vaccine in Puerto Rico

Dengue vaccine draft recommendations using the evidence to recommendation 

framework

Dengue VFC Resolution

Dr. Wilbur Chen (ACIP, WG Co-Chair)

Dr. Ines Esquilin (University of Puerto Rico, School of Medicine)

Dr. Iris Cardona (Department of Health, Puerto Rico)

Dr. Gabriela Paz-Bailey (CDC/NCEZID)

Dr. Jeanne Santoli (CDC/NCIRD)

12:20

12:30 Influenza Vaccines 

Introduction

Flucelvax Quadrivalent (ccIIV4) Phase III Randomized Controlled 

Trial—Immunogenicity and Safety in Children 6 through 47 months

Work group considerations and proposed recommendations for the 2021-22 

Influenza Season

Updates to Influenza VFC Resolution

Dr. Keipp Talbot (ACIP, WG Chair)

Dr. Gregg Sylvester (Seqirus)

Dr. Lisa Grohskopf (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

2:10

2:20 Rabies Vaccines 

Introduction

Rabies immune globulin 

Rabies post-exposure prophylaxis schedule 

Rabies pre-exposure prophylaxis: GRADE/EtR summary 

Dr. Sharon Frey (ACIP, WG Chair)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

3:40

3:45

4:15

4:20 Votes and VFC Votes 

Dengue Vaccine

Dengue Vaccine (VFC)

Influenza Vaccines

Influenza Vaccine (VFC)

Rabies Vaccines

Dr. Gabriela Paz-Bailey (CDC/NCEZID)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Lisa Grohskopf (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Agam Rao (CDC/NCEZID)

5:15

Public Comment 

Break

Break

Break

Break

Discussion 

COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion

Discussion

Break

Public Comment

Overview of data to inform recommendations for additional doses of COVID-19 

vaccines

Adjourn

Adjourn

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

June 23-25, 2021

Wednesday, June 23, 2021

11:00 Welcome & Introductions

Thursday, June 24, 2021

10:00 Welcome & Introductions

Break

page 1 of 2
Draft - June 21, 2021

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:15 Zoster Vaccines 

Introduction

Burden of herpes zoster in immunocompromised adults

Use of recombinant zoster vaccine in immunocompromised populations: overview of 

clinical program

Dr. Grace Lee (ACIP, WG Chair)

Dr. Tara Anderson (CDC/NCIRD)

Ms. Robyn Widenmaier (GSK)

11:05 Pneumococcal Vaccines 

Introduction

Updates on epidemiology of invasive pneumococcal disease in U.S. adults

Cost effectiveness of PCV15 and PCV20 use in U.S. adults

GRADE for age-based PCV15 and PCV20 use in U.S. adults

EtR summary of age-based PCV15 and PCV20 use in U.S. adults

Summary and Timeline

Dr. Kathy Poehling (ACIP, WG Chair)

Mr. Ryan Gierke (CDC/NCIRD)

Dr. Charles Stoecker (Tulane University)

Ms. Jennifer Farrar (CDC/NCIRD)

Dr. Miwako Kobayashi (CDC/NCIRD)

Dr. Miwako Kobayashi (CDC/NCIRD)

1:00

Acronyms

CDC

CMS

COVID-19

EtR

FDA

GRADE

HRSA

IHS

NCHHSTP

NCIRD

NCEZID

NIAID

OIDP

PCV15 15-Valent Pneumococcal Conjugate Vaccine

PCV20 20-Valent Pneumococcal Conjugate Vaccine

SARS-CoV-2

WG

WHO

VE

Severe Acute Respiratory Syndrome Coronavirus 2

Work Group

World Health Organization

Vaccine Effectiveness

Centers for Disease Control and Prevention

Centers for Medicare and Medicaid Services 

Evidence to Recommendations Framework

Grading of Recommendations Assessment, Development and Evaluation

Health Resources and Services Administration

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/DDID] 

National Center for Immunization & Respiratory Diseases [of CDC/DDID] 

National Center for Emerging and Zoonotic Diseases [of CDC/DDID]

National Institute of Allergy and Infectious Diseases

Office of Infectious Disease and HIV/AIDS Policy

Indian Health Service

Food and Drug Administration

Coronavirus Disease 2019

Friday, June 25, 2021

10:00 Welcome & Introductions

Adjourn

page 2 of 2